Company Name: |
Hangzhou MolCore BioPharmatech Co.,Ltd. |
Tel: |
+86-057181025280; +8617767106207 |
Email: |
sales@molcore.com |
Products Intro: |
Product Name:1H-Cyclopropa[4,5]pyrrolo[1,2-a]pyrazine-3,6-dione, hexahydro-4-(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)-, (1aS,4S,6aR,7aS)- CAS:1350800-77-9 Purity:95%+ Remarks:MC734387
|
|
|
|
|
Company Name: |
Jiangsu Vcare PharmaTech Co., Ltd.
|
Tel: |
025-58741518; 18013018875 |
Email: |
sales@vcarepharmatech.com |
Products Intro: |
Product Name:1H-Cyclopropa[4,5]pyrrolo[1,2-a]pyrazine-3,6-dione, hexahydro-4-(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)-, (1aS,4S,6aR,7aS)- CAS:1350800-77-9
|
|
| 1H-Cyclopropa[4,5]pyrrolo[1,2-a]pyrazine-3,6-dione, hexahydro-4-(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)-, (1aS,4S,6aR,7aS)- Basic information |
Product Name: | 1H-Cyclopropa[4,5]pyrrolo[1,2-a]pyrazine-3,6-dione, hexahydro-4-(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)-, (1aS,4S,6aR,7aS)- | Synonyms: | Saxagliptin Dione Impurity;(1aS,4S,6aR,7aS)-4-(3-hydroxy-1-adamantyl)-1a,4,5,6a,7,7a-hexahydro-1H-cyclopropa[3,4]pyrrolo[3,5-c]pyrazine-3,6-dione;Saxagliptin Cyclic Amide;(1aS,4S,6aR,7aS)-4-((1r,3R,5R,7S)-3-hydroxyadamantan-;Saxagliptin Impurity 7 HCl;(1aS,4S,6aR,7aS)-4-((1r,3R,5R,7S)-3-hydroxyadamantan-1-yl)tetrahydro-1H-cyclopropa[4,5]pyrrolo[1,2-a]pyrazine-3,6(1aH,6aH)-dione;(1aS,4S,6aR,7aS)-4-((1r,3R,5R,7S)-3-hydroxyadamantan-1-yl)hexahydro-1H-cyclopropa[4,5]pyrrolo[1,2-a]pyrazine-3,6-dione;Saxagliptin Impurity 9(BMS-700047) | CAS: | 1350800-77-9 | MF: | C18H24N2O3 | MW: | 316.39 | EINECS: | | Product Categories: | | Mol File: | 1350800-77-9.mol | |
| 1H-Cyclopropa[4,5]pyrrolo[1,2-a]pyrazine-3,6-dione, hexahydro-4-(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)-, (1aS,4S,6aR,7aS)- Chemical Properties |
| 1H-Cyclopropa[4,5]pyrrolo[1,2-a]pyrazine-3,6-dione, hexahydro-4-(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)-, (1aS,4S,6aR,7aS)- Usage And Synthesis |
Uses | Saxagliptin Cyclic Amide is a degradation product of Saxagliptin (S143500); a potent and selective reversible inhibitor of dipeptidyl peptidase-4 (DPP-IV) developed for the treatment of type 2 diabetes. |
| 1H-Cyclopropa[4,5]pyrrolo[1,2-a]pyrazine-3,6-dione, hexahydro-4-(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)-, (1aS,4S,6aR,7aS)- Preparation Products And Raw materials |
|